Results 101 to 110 of about 603,480 (300)
Genetics and insurance in the United Kingdom 1995-2010: the rise and fall of scientific discrimination [PDF]
, 2012 Around the millennium there was extensive debate in the United Kingdom of the possible use of predictive genetic tests by insurance companies. Many insurance experts, geneticists and public policymakers appeared to believe that genetic test results would
Thomas, R. Guy
core +1 more source
Barriers and Enablers for Effective Support Coordination in the National Disability Insurance Scheme
Australian Journal of Social Issues, EarlyView.ABSTRACT Support coordinators act as intermediaries between the National Disability Insurance Scheme (NDIS) and participants, facilitating access to funded supports. To optimise outcomes, they must navigate NDIS complexities, identify services that meet individual needs and engage with diverse stakeholders.
Sharyn McDonald +3 more
wiley +1 more source
RisksInsurance pricing is the process of determining the premiums that policyholders pay in exchange for insurance coverage. In order to estimate premiums, actuaries use statistical based methods, assessing various factors such as the probability of certain ...
Robin Van Oirbeek +5 more
doaj +1 more source
Dynamic Financial Analysis - Understanding Risk and Value Creation in Insurance [PDF]
The changing business environment in non-life insurance and reinsurance has raised the need for new quantitative methods to analyze the impact of various types of strategic decisions on a company’s bottom line.
Michel Dacorogna, Peter Blum
core
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is managed after sinus surgery with topical corticosteroids. Given limited distribution of nasal steroid sprays, patients have the option of either steroid nasal irrigation (SNI) or exhalation delivery system with fluticasone (EDS‐FLU).
Daniel Xiao +3 more
wiley +1 more source
Animal Models and Experimental Medicine, EarlyView.Directed differentiation of pluripotent stem cells into functional pancreatic β cells have emerged as a promising strategy for the radical treatment of type 1 diabetes, with preclinical and early clinical evidence demonstrating reversal of hyperglycemia and insulin independence.
Zifan Li, Yu Kang, Yuyu Niu
wiley +1 more source
Trends and Current Situation of China's Meat Sector
Animal Research and One Health, EarlyView.ABSTRACT As the world's largest meat producer, consumer, and importer, China's meat sector has undergone profound transformation over the past decade, driven by biological crises (e.g., African Swine Fever), environmental policies, and global market integration. This study analyzes the sector's production restructuring, consumption diversification, and
Zengyong Zhu
wiley +1 more source
Changes of Market Structure and Competition in the Croatian (Non)Life Insurance Industry
The business review, Cambridge, 2011 Until the nineties of the last century, the Croatian insurance market used to be highly concentrated. However, with the entrance of foreign capital and private investors, market structure and level of competition significantly changed. From former almost monopolistic situation with only one (or a few) state owned insurance companies operating on it ...
Pervan, Maja +2 more
openaire +2 more sources
Cost efficiency and profitability in Thailand's life insurance industry: A stochastic cost frontier approach [PDF]
, 2005 Liberalized environments brought about by trade agreements and other restructuring of international markets under the General Agreement on Trade and Services (GATS) have increased market opportunities for foreign firms. This opening up of domestic market
Abd Karim, Mohd Zaini
core
Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans
Arthritis &Rheumatology, EarlyView.Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon +2 more
wiley +1 more source